ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Other Events
Item 8.01
ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Other Events
On June 19, 2019, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release (the “Release”) announcing an expanded research collaboration and license agreement between the Company and Arcturus Therapeutics Holdings, Inc. (“Arcturus”), including an equity investment by the Company in Arcturus.
A copy of the Release is filed as Exhibit 99.1.
(d) Exhibits
* * *
Ultragenyx Pharmaceutical Inc. Exhibit
EX-99.1 2 rare-ex991_6.htm EX-99.1 rare-ex991_6.htm Exhibit 99.1 Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases • Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA,…
To view the full exhibit click here
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
